ConvaTec Group PLC Director/PDMR Shareholding (4360Z)
17 Maggio 2019 - 01:30PM
UK Regulatory
TIDMCTEC
RNS Number : 4360Z
ConvaTec Group PLC
17 May 2019
17 May 2019
ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding
The Company has been notified of the following transaction by a
Person Discharging Managerial Responsibility ("PDMR") in ordinary
shares of 10 pence each in the share capital of the Company
("Shares").
On 16 May 2019 Mr Rick Anderson, Executive Chairman and Chief
Executive Officer, acquired 1,680 Shares at GBP1.3728 per share as
part of the Scrip Dividend Scheme. Mr Anderson's resulting
shareholding is 206,655 Shares.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Mr Rick Anderson
2 Reason for the notification
a) Position/Status Executive Chairman and Chief Executive Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name ConvaTec Group Plc
b) LEI 213800LS272L4FIDOH92
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the financial Ordinary shares of 10p each in ConvaTec Group Plc ("Shares")
instrument, type of instrument
Identification code GB00BD3VFW73
b) Nature of the transaction Acquisition of Shares via Scrip Dividend Scheme
c) Price(s) and volume(s) Price(s) Volume(s)
GBP1.3728 1680
d) Aggregated information
- Aggregated volume 1680
- Price GBP2,306.31
e) Date of the transaction 16 May 2019
f) Place of the transaction London Stock Exchange, Main Market (XLON)
Enquiries
Media
Bobby Leach, VP Group Corporate Affairs, ConvaTec +44 (0)7770 842 226
Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec +44 (0)7500 141 435
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
investorrelations@convatec.com
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion devices. ConvaTec's
products provide a range of clinical and economic benefits
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care. To learn
more about ConvaTec, please visit www.convatecgroup.com where a
copy of this announcement can also be found.
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFILESIDLIA
(END) Dow Jones Newswires
May 17, 2019 07:30 ET (11:30 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2023 a Mar 2024